Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

John van der Valk Appointed MD of UBM Live Amsterdam

Published: Monday, December 23, 2013
Last Updated: Sunday, December 22, 2013
Bookmark and Share
Valk responsible for overseeing the company’s flagship brand CPhI.

UBM Live has announced the appointment of John van der Valk as the new Managing Director of the UBM Live Amsterdam business.

His responsibilities will include the management of the pharma portfolio including the Company’s flagship brand CPhI Worldwide, which continues to evolve as the leading pharmaceutical event globally.

As part of his new role, John is focusing on the integration of digital media within the live events portfolio. One example is the CPhI Online directory, which provides pharmaceutical buyer’s access to the CPhI database of the industry’s foremost suppliers, including a search function for individual services and products.

The ultimate goal is to make it easier for exhibitors to meet with international pharmaceutical companies, stay informed about the latest industry trends and remain ahead of a constantly changing pharmaceutical market.

John has over 15 years' experience within the events and media business, and comes to UBM Live from VNU. He has extensive knowledge of large-scale trade and consumer shows, digital marketing services, partner relationships and product development.

"I am delighted that John has joined the UBM Live team. John's experience and expertise is invaluable to his leadership of the Food and Pharma portfolios as we continue to focus on our customer's needs, and the deliverance of outstanding customer experience," stated Simon Foster, CEO of UBM Live.

Foster continued, "John's contributions to the UBM Live Board, and to our global collaborations for growth and development of the business, play a significant role."

Commenting on his appointment, John van der Valk remarked, "It is a really exciting time to be joining UBM Live as we build a global portfolio of industry leading pharma events. Working alongside Chris Kilbee, together we look forward to helping grow the pharma portfolio so that CPhI Worldwide and sister events continue to drive growth, partnerships and business across the pharma industry. Our aims for 2014 are to launch our events in new markets and to expand the scope of content we provide so that we can help industry stay in touch year round.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Demand for International Pharma Manufacturers and Ingredients Increasing in Russia
CPhI Russia 2016 opens as the country is seeking rapid upgrades to GMP standards.
Wednesday, February 24, 2016
CPhI Worldwide Introduce New Event
Expanding its reputation as a global hub for the final dose supply chain is a key strategy for CPhI in 2016.
Wednesday, February 17, 2016
CPhI Worldwide Launches Pharma Insights 2016 USA Report at InformEx 2016
CPhI report warns international manufacturers about the need to invest in domestic US sites and indicates that US CDMOs are well placed to keep biosimilars development work into commercialisation.
Friday, February 05, 2016
CPhI Worldwide Closes with Growth Forecast in FDI and Latin American Exports
Event sees record exhibitor attendance and is set to return to thriving Spain in 2016.
Friday, December 18, 2015
CPhI Report Highlights Acquisitions of Niche Technologies
Medium term prospects for contract services remain positive (both developed and emerging markets), despite fragmented biosimilar regulation and GDUFA fees.
Thursday, October 15, 2015
#CPhIChat Returns to CPhI Worldwide for the Second Successive Year
Pharma community is encouraged to lend their views on key industry issues.
Saturday, October 10, 2015
CPhI Experts Predict Continuous Manufacturing for All Within 10-years
Brian Carlin emphasizes need to build flexibility into design to manage impact of raw material variability through product lifecycle.
Thursday, October 01, 2015
CPhI & P-MEC China Closes as the Chinese Domestic Market Continues to Expand
International companies looking to gain a foothold in this lucrative and gentrifying pharma economy.
Tuesday, August 11, 2015
CPhI Korea Opens as South Korea Emerges as Global Leader in Biosimilar Trials
Government’s R&D strategy and “Pharma 2020 Vision” to see country as drug development leader.
Monday, July 27, 2015
CPhI Announces USA Market Report at InformEx
Country report to contain contrasting insights into the American pharma economy from European and domestic perspectives.
Wednesday, January 22, 2014
Chris Kilbee Appointed Group Director of UBM Pharma Portfolio
Kilbee responsible for driving the portfolio globally including increased emphasis on digital and content.
Monday, January 13, 2014
CPhI Japan 2014: Japanese Market to Continue to Dominate Global Pharma
Growth in the World’s second largest pharma region facilitated by innovation and loosened regulatory guidelines.
Monday, December 30, 2013
Rise of Generics and Patent Expirations Sees CPhI and P-MEC India 2013 Expand
Free online registration to attend CPhI and P-MEC India is now closed.
Tuesday, December 03, 2013
CPhI Worldwide 2013 Hosted More Than 34,000 Global Pharma Professionals
This year sees strong growth in APIs, biopharma, natural extracts, packaging and finished dosage with a highlight on innovation.
Tuesday, November 26, 2013
India Sets Ambitious Pharma Export Growth Targets
Indian generics exports growing at 24% per annum.
Monday, October 21, 2013
Scientific News
Investigational Malaria Vaccine Protects Healthy U.S. Adults
Researchers at NIH have found that the malaria vaccine protected a small number of healthy, malaria-naïve adults in the U.S. from infection for more than one year after immunization.
AACR 2016: Cancer Immunotherapy and Beyond
At this year's meeting there was a palpable buzz around subjects ranging from microbiomics to the tumor microenvironment and cancer vaccines, big data to in vitro and in vivo modeling and drug delivery (to name just a few).
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
Treatment of Common Prostate Cancer
Researchers at UTSW have found that the prostate cancer treatments suppress immune response and may promote relapse.
Cancer Drug Could Treat Blood Vessel Deformities
A drug currently being trialled in cancer patients could also be used to treat an often incurable condition that can cause painful blood vessel overgrowths inside the skin.
Structure of Crucial Enzyme Identified
Researchers at UTSW have determined the atomic structure of an enzyme that plays an essential role in cell division and better treatment of cancer.
New Immunotherapy Trial for Type 1 Diabetes
The search for a treatment for Type 1 diabetes (T1D) - which affects over 400,000 people in the UK – will be stepped up with the start of a new phase one clinical trial at Guy’s Hospital in London.
Recruitment of First Patient in Clinical Study
Company has announced recruitment of first patient in clinical study assessing Visco-ease with Beatson Cancer Centre for the treatment of RIX.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!